Table 4.
Multivariate analysis of factors associated with MACE.
| Variables | Adjusted HR (95% CI) | p-value |
|---|---|---|
| *Post-ablation LAVI (/1 mL/m2 increase) | 1.02 (1.01–1.04) | < 0.001 |
| Post-ablation LARR (/1% increase) | 0.98 (0.97–1.004) | 0.162 |
| *Age (/1 year increase) | 1.05 (1.01–1.09) | 0.005 |
| Female | 1.04 (0.56–1.93) | 0.900 |
| Pre-ablation LVEF (/1% increase) | 0.97 (0.95–1.00) | 0.051 |
| Arrhythmic recurrence at 3 months post-ablation | 0.90 (0.45–1.77) | 0.763 |
| *Pre-ablation BNP (/1 pg/mL increase) | 1.0001 (1.0002–1.002) | 0.017 |
| History of HF hospitalization | 1.65 (0.84–3.23) | 0.139 |
| Pre-ablation eGFR level (/1 mL/min/1.73m2 increase) | 0.99 (0.97–1.01) | 0.322 |
| Any structural heart disease | 1.07 (0.58–1.97) | 0.809 |
BNP brain natriuretic peptide, CI confidence interval, eGFR estimated glomerular filtration rate, HF heart failure, HR hazard ratio, LARR left atrial reverse remodeling, LAVI left atrial volume index, LVEF left ventricular ejection fraction, MACE major adverse cardiovascular events.
Asterisks indicate statistical significance (*p < 0.05).